Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2014-03-06 Annual Report
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
10-K Filing
Annual Report FY 2013
2014-03-06 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 6, 2014, for Insmed Incorporated. It specifically references Item 2.02 - Results of Operations and Financial Condition, and mentions a press release regarding financial results for the quarter and year ended December 31, 2013. The document states that the press release is furnished as Exhibit 99.1 and is not deemed filed for certain regulatory purposes. The document length is 3041 characters, which is relatively short and primarily serves as a current report announcing the release of financial results via a press release. This matches the characteristics of an Earnings Release (ER) filing, which is the initial announcement of quarterly or periodical financial results with key highlights. It is not a full annual report or interim report, nor is it a regulatory filing or report publication announcement. Therefore, the correct classification is Earnings Release (ER).
2014-03-06 English
8-K Filing
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions an "Other Events" section describing a press release about a study update, and includes the press release as an exhibit. The document length is 2749 characters, which is relatively short and mainly serves as an announcement rather than a full report. There are no financial statements or detailed financial data included. The document is not an annual or quarterly report, nor is it a transcript, proxy, or governance document. It is a regulatory filing used to disclose a specific event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-02-19 English
SC 13G/A Filing
Major Shareholding Notification
2014-02-14 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement between the company and another party, detailing the contract manufacturing agreement terms. There are no financial statements or quarterly/yearly financial results presented. The document is not an earnings release, annual report, or interim report. It is a regulatory announcement of a significant contract event. Therefore, the filing type corresponds to a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2014-02-11 English
SC 13G/A Filing
Major Shareholding Notification
2014-02-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.